Cologuard is a non-invasive stool DNA test that is more effective and has higher patient compliance than other colon cancer screening options. It has received FDA approval and Medicare coverage, addressing a large underserved screening market. Exact Sciences is expanding insurance coverage and physician adoption of Cologuard to increase screening rates and detect more curable-stage cancers. First quarter 2016 revenue was $14.8 million as adoption grows.
This corporate presentation discusses the company's mission to help eradicate colon cancer. It summarizes the challenges of colon cancer as the second deadliest cancer in the U.S. and highlights Cologuard, the company's non-invasive stool DNA test, as a way to address low screening rates and detect precancerous polyps. Data shows Cologuard has strong performance in detecting cancer and precancer, and its inclusion in guidelines is expected to help make it the standard of care for colon cancer screening.
- The corporate presentation discusses Exact Sciences' colorectal cancer screening test, Cologuard.
- Cologuard is a non-invasive stool DNA test that is FDA-approved and covered by Medicare for average-risk individuals ages 50-85. Clinical trials have shown it to be 92% sensitive in detecting cancer and 42% sensitive in detecting advanced precancer.
- Exact Sciences believes Cologuard can help increase low U.S. colorectal cancer screening rates by offering a convenient and effective screening option that has achieved high patient compliance compared to other tests.
September 2016-corporate-presentation-finalExact Sciences
The document is a corporate presentation from Exact Sciences that discusses:
1) Cologuard, a non-invasive stool DNA screening test for colorectal cancer that is FDA approved and gaining insurance coverage.
2) Exact Sciences' strategy to increase adoption of Cologuard through physician and patient education, national marketing campaigns, and expanding insurance reimbursement.
3) Progress made in 2016, including growing test volumes, revenue guidance of $90-100 million for the year, and a cash balance of $224.1 million as of the second quarter.
November 2016 corporate presentation final1Exact Sciences
This corporate presentation discusses Exact Sciences' Cologuard test for colorectal cancer screening. It summarizes Cologuard's strong clinical trial results and inclusion in leading cancer screening guidelines. The presentation also outlines Exact Sciences' strategy to drive adoption of Cologuard through their sales force, marketing campaigns, and work to expand insurance coverage. Exact Sciences expects Cologuard use to continue growing significantly in 2016 and beyond as more providers and patients are exposed to the test.
This corporate presentation provides an overview of Exact Sciences and its colorectal cancer screening product Cologuard. It summarizes Cologuard's clinical trial results, performance metrics, inclusion in guidelines, and commercial strategy. The presentation outlines Exact Sciences' mission to help eradicate colon cancer through an early detection test. It also reviews Cologuard's growing adoption rates, coverage expansion, and financial results indicating increased revenue and ongoing cash availability to support commercialization efforts.
Exact Sciences Corporate Presentation: April 2016Exact Sciences
The corporate presentation discusses colon cancer as the second deadliest cancer in the United States and highlights the need for improved screening rates. It summarizes the performance of Cologuard, Exact Sciences' non-invasive stool DNA screening test, including superior cancer detection rates compared to other screening methods based on clinical trials and studies. The presentation outlines Exact Sciences' commercial strategy to increase awareness of Cologuard among physicians, payers, and patients with the goal of driving compliance and access to colon cancer screening.
Exact Sciences presented its second quarter 2018 corporate presentation. The presentation highlighted Cologuard's continued strong growth, with over 1.1 million people screened and thousands of pre-cancerous polyps and early-stage cancers detected. Cologuard's compliance rate of 68% is significantly higher than other screening options due to its ease of use and patient support services. The presentation demonstrated Cologuard's potential to become the leading screening test for colorectal cancer in the United States through its multi-billion dollar addressable market.
This corporate presentation discusses the company's mission to help eradicate colon cancer. It summarizes the challenges of colon cancer as the second deadliest cancer in the U.S. and highlights Cologuard, the company's non-invasive stool DNA test, as a way to address low screening rates and detect precancerous polyps. Data shows Cologuard has strong performance in detecting cancer and precancer, and its inclusion in guidelines is expected to help make it the standard of care for colon cancer screening.
- The corporate presentation discusses Exact Sciences' colorectal cancer screening test, Cologuard.
- Cologuard is a non-invasive stool DNA test that is FDA-approved and covered by Medicare for average-risk individuals ages 50-85. Clinical trials have shown it to be 92% sensitive in detecting cancer and 42% sensitive in detecting advanced precancer.
- Exact Sciences believes Cologuard can help increase low U.S. colorectal cancer screening rates by offering a convenient and effective screening option that has achieved high patient compliance compared to other tests.
September 2016-corporate-presentation-finalExact Sciences
The document is a corporate presentation from Exact Sciences that discusses:
1) Cologuard, a non-invasive stool DNA screening test for colorectal cancer that is FDA approved and gaining insurance coverage.
2) Exact Sciences' strategy to increase adoption of Cologuard through physician and patient education, national marketing campaigns, and expanding insurance reimbursement.
3) Progress made in 2016, including growing test volumes, revenue guidance of $90-100 million for the year, and a cash balance of $224.1 million as of the second quarter.
November 2016 corporate presentation final1Exact Sciences
This corporate presentation discusses Exact Sciences' Cologuard test for colorectal cancer screening. It summarizes Cologuard's strong clinical trial results and inclusion in leading cancer screening guidelines. The presentation also outlines Exact Sciences' strategy to drive adoption of Cologuard through their sales force, marketing campaigns, and work to expand insurance coverage. Exact Sciences expects Cologuard use to continue growing significantly in 2016 and beyond as more providers and patients are exposed to the test.
This corporate presentation provides an overview of Exact Sciences and its colorectal cancer screening product Cologuard. It summarizes Cologuard's clinical trial results, performance metrics, inclusion in guidelines, and commercial strategy. The presentation outlines Exact Sciences' mission to help eradicate colon cancer through an early detection test. It also reviews Cologuard's growing adoption rates, coverage expansion, and financial results indicating increased revenue and ongoing cash availability to support commercialization efforts.
Exact Sciences Corporate Presentation: April 2016Exact Sciences
The corporate presentation discusses colon cancer as the second deadliest cancer in the United States and highlights the need for improved screening rates. It summarizes the performance of Cologuard, Exact Sciences' non-invasive stool DNA screening test, including superior cancer detection rates compared to other screening methods based on clinical trials and studies. The presentation outlines Exact Sciences' commercial strategy to increase awareness of Cologuard among physicians, payers, and patients with the goal of driving compliance and access to colon cancer screening.
Exact Sciences presented its second quarter 2018 corporate presentation. The presentation highlighted Cologuard's continued strong growth, with over 1.1 million people screened and thousands of pre-cancerous polyps and early-stage cancers detected. Cologuard's compliance rate of 68% is significantly higher than other screening options due to its ease of use and patient support services. The presentation demonstrated Cologuard's potential to become the leading screening test for colorectal cancer in the United States through its multi-billion dollar addressable market.
Corporate Presentation - Third Quarter 2018Exact Sciences
This corporate presentation provides an overview of Exact Sciences' third quarter 2018 results and outlook. It discusses the company's vision of helping win the war on cancer through early detection. Exact Sciences offers Cologuard, a non-invasive stool DNA test to screen for colorectal cancer. Cologuard has shown high sensitivity for early-stage cancer detection and increased patient compliance with screening. The presentation reviews clinical trial results and outlines the significant market opportunity for colorectal cancer screening in the US and globally. Exact Sciences is also exploring opportunities to expand Cologuard's use and develop additional cancer screening tests using blood-based biomarkers.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Exact Sciences December 2015 Corporate PresentationExact Sciences
This corporate presentation discusses Exact Sciences' colorectal cancer screening test Cologuard. It summarizes Cologuard's strong clinical performance in detecting cancer and precancer, growing physician awareness and adoption, expanding insurance coverage, and high patient compliance rate driven by Exact Sciences' comprehensive screening program. The presentation also outlines Exact Sciences' growth strategies to further drive demand and market share for Cologuard.
December 2016 exas corporate presentation final 12.12Exactir
- The corporate presentation provides an overview of the company's mission to help eradicate colon cancer through its Cologuard product.
- Cologuard is a non-invasive stool DNA test that is 92% sensitive at detecting colorectal cancer and has an 87% specificity. It addresses the large gap in colon cancer screening rates in the United States.
- The company has a strategy to increase adoption of Cologuard through expanding insurance coverage, increasing guidelines inclusion, driving quality measures, and growing awareness through its national TV and digital marketing campaigns.
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
This presentation provides an overview of Exact Sciences' first quarter 2018 performance. It discusses the company's vision of helping win the war on cancer through early detection. Key points include that Cologuard continues to drive strong revenue and test volume growth, with over 1 million people screened and increasing average reimbursement per test. Customer satisfaction with Cologuard also remains high among both providers and patients.
The document provides an overview of Exact Sciences and its colorectal cancer screening test Cologuard. It discusses Cologuard's performance in clinical trials, cost-effectiveness, growing adoption rates, and commercial strategy to increase screening rates in the US. Exact Sciences expects over 240,000 Cologuard tests to be completed in 2016, up from 104,000 in 2015, and revenue is forecasted to be between $90-100 million.
Exas may 2017 corporate presentation final1Exact Sciences
Exact Sciences is developing a pipeline of cancer diagnostic tests based on its methylation technology platform. It has validated methylation markers for the detection of lung, liver, and pancreatic cancers from blood samples, achieving sensitivity of 91-95% and specificity of 90-97%. The company's goal is to apply its platform to screen for and monitor additional cancers through liquid biopsy tests to enable earlier detection and guide treatment decisions. Exact Sciences reported first quarter 2017 revenues of $48.4 million, up from $35.2 million in the previous quarter, demonstrating accelerating adoption of its Cologuard colorectal cancer screening test.
Exas july 2017 corporate presentation finalExact Sciences
This corporate presentation discusses Exact Sciences' mission to help eradicate colon cancer through early detection. It summarizes the company's Cologuard test, which detects colorectal cancer through a non-invasive stool DNA test. The presentation outlines Cologuard's clinical validation and success in increasing early cancer detection rates and patient compliance with screening. It also reviews Exact Sciences' commercial strategy, growth opportunities, and expanding pipeline of non-invasive liquid biopsy tests to detect additional cancers.
3.31.17 exas april 2017 corporate presentationExact Sciences
This corporate presentation discusses Exact Sciences' mission to help eradicate colon cancer by partnering with various stakeholders. It summarizes the company's Cologuard test, which non-invasively screens for colorectal cancer with high sensitivity. Cologuard saw strong growth in 2016 and the presentation outlines Exact Sciences' commercial strategy and pipeline expansion into liquid biopsy tests for additional cancer types in collaboration with Mayo Clinic.
3.31.17 exas april 2017 corporate presentation v2Exact Sciences
Exact Sciences is working to establish Cologuard as the new standard for colon cancer screening by:
1) Increasing adoption through a national TV campaign and primary care sales force focused on educating physicians.
2) Growing revenue and test volume rapidly, with 152% revenue growth and over 68,000 tests completed in Q4 2016.
3) Expanding coverage with 77% of the addressable population now covered, including Medicare, following inclusion in screening guidelines.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
This document provides an overview of Cancer Genetics, Inc. It discusses the company's focus on empowering personalized cancer treatment through molecular diagnostics. The summary highlights Cancer Genetics' proprietary diagnostic products for various cancers, partnerships with biopharma companies, growth in revenue and testing volume in 2013, and pipeline of diagnostic tests in development. It also outlines the company's business model and strategy to commercialize its products to target markets globally.
Cancer immunotherapy is becoming a mainstream treatment for cancer. It works by activating the body's own immune system to attack cancer cells. Immunotherapy treatments include checkpoint inhibitors that help activate T cells to kill tumors, and cancer vaccines that stimulate the immune system. Immunotherapy is now approved for several types of cancer and is being studied in combination with other therapies to make treatments more effective with fewer side effects than chemotherapy.
FLAACOs 2014 Conference - Cancer Care in an ACO LandscapeMARCYINC
This document provides an overview of cancer care in Accountable Care Organizations (ACOs) presented by Kelly Blair, COO of Oncology Resource Networks. It notes that cancer costs are rising without improved quality. The landscape is evolving towards value-based contracts between payers and providers and more ACOs. Oncology presents challenges for ACOs due to its complexity and costs, but oncologists are well-suited in some ways. The document provides advice on exploring partnerships with like-minded providers and establishing patient-centered care, aligned incentives, evidence-based guidelines, and monitoring performance to improve outcomes and lower costs in high-performing oncology networks.
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Join our presenters, Wayne Critchley from Global Public Affairs and Ryan Clarke from Advocacy Solutions, and CCSN to learn more about changes to the Patented Medicine Prices Review Board (PMPRB) and receive guidance about how to support the cancer community’s engagement at this stage of regulatory reform.
View the video:
https://youtu.be/4IsiptCD0Tw
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Designed this online educational booklet for Association of Community Cancer ...Vickie Spindler
This document summarizes the findings from a focus group and survey conducted by the Association of Community Cancer Centers (ACCC) regarding venous thromboembolism (VTE) risk assessment, prevention, and management for cancer patients in outpatient settings. The focus group and survey found significant variability in VTE risk assessment and documentation. Few oncology practices have formal protocols for VTE risk assessment or use tools to calculate risk. Additionally, VTE prevention and education for patients is not standardized. The document provides opportunities for improvement, including developing formal VTE assessment and order protocols, incorporating risk assessment into electronic health records, and improving patient education about VTE risk and prevention.
Exact Sciences Corporate Presentation: June 2016Exact Sciences
- The corporate presentation provides an overview of the company's mission to help eradicate colon cancer through partnerships with various stakeholders. It highlights key facts about colon cancer incidence and mortality rates.
- Cologuard, the company's non-invasive stool DNA screening test, is described as addressing the colon cancer challenge through multi-target screening with high sensitivity and specificity rates confirmed in clinical studies.
- The presentation outlines the large market opportunity for Cologuard given the underutilized colon cancer screening rates in the US and Cologuard's inclusion in medical guidelines and recommendations.
This corporate presentation provides an overview of Exact Sciences and its colorectal cancer screening test Cologuard. It summarizes Cologuard's clinical trial results showing high sensitivity and specificity. The presentation outlines the large market opportunity for Cologuard given the prevalence of colorectal cancer and low screening rates in the US. Exact Sciences' commercial strategy includes expanding insurance coverage, increasing physician adoption through sales and marketing efforts, and driving patient demand with a national TV advertising campaign. Financial guidance projects over $90 million in revenue and processing over 240,000 Cologuard tests in 2016.
Corporate Presentation - Third Quarter 2018Exact Sciences
This corporate presentation provides an overview of Exact Sciences' third quarter 2018 results and outlook. It discusses the company's vision of helping win the war on cancer through early detection. Exact Sciences offers Cologuard, a non-invasive stool DNA test to screen for colorectal cancer. Cologuard has shown high sensitivity for early-stage cancer detection and increased patient compliance with screening. The presentation reviews clinical trial results and outlines the significant market opportunity for colorectal cancer screening in the US and globally. Exact Sciences is also exploring opportunities to expand Cologuard's use and develop additional cancer screening tests using blood-based biomarkers.
Exact Sciences 2015 J.P Morgan Healthcare Conference PresentationExact Sciences
Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.
Exact Sciences December 2015 Corporate PresentationExact Sciences
This corporate presentation discusses Exact Sciences' colorectal cancer screening test Cologuard. It summarizes Cologuard's strong clinical performance in detecting cancer and precancer, growing physician awareness and adoption, expanding insurance coverage, and high patient compliance rate driven by Exact Sciences' comprehensive screening program. The presentation also outlines Exact Sciences' growth strategies to further drive demand and market share for Cologuard.
December 2016 exas corporate presentation final 12.12Exactir
- The corporate presentation provides an overview of the company's mission to help eradicate colon cancer through its Cologuard product.
- Cologuard is a non-invasive stool DNA test that is 92% sensitive at detecting colorectal cancer and has an 87% specificity. It addresses the large gap in colon cancer screening rates in the United States.
- The company has a strategy to increase adoption of Cologuard through expanding insurance coverage, increasing guidelines inclusion, driving quality measures, and growing awareness through its national TV and digital marketing campaigns.
Investor & Analyst Day 2015: Cologuard Expansion (2/8)Exact Sciences
This document discusses Exact Sciences' Cologuard home screening test for colorectal cancer. It summarizes early results from the launch, including that the number of physicians ordering and patients using Cologuard is growing rapidly. Over 13,000 physicians have ordered Cologuard already. The document also outlines strategies to further expand adoption, including securing insurance coverage, influencing medical guidelines, and activating patients. The goal is to screen millions more Americans for colorectal cancer.
This presentation provides an overview of Exact Sciences' first quarter 2018 performance. It discusses the company's vision of helping win the war on cancer through early detection. Key points include that Cologuard continues to drive strong revenue and test volume growth, with over 1 million people screened and increasing average reimbursement per test. Customer satisfaction with Cologuard also remains high among both providers and patients.
The document provides an overview of Exact Sciences and its colorectal cancer screening test Cologuard. It discusses Cologuard's performance in clinical trials, cost-effectiveness, growing adoption rates, and commercial strategy to increase screening rates in the US. Exact Sciences expects over 240,000 Cologuard tests to be completed in 2016, up from 104,000 in 2015, and revenue is forecasted to be between $90-100 million.
Exas may 2017 corporate presentation final1Exact Sciences
Exact Sciences is developing a pipeline of cancer diagnostic tests based on its methylation technology platform. It has validated methylation markers for the detection of lung, liver, and pancreatic cancers from blood samples, achieving sensitivity of 91-95% and specificity of 90-97%. The company's goal is to apply its platform to screen for and monitor additional cancers through liquid biopsy tests to enable earlier detection and guide treatment decisions. Exact Sciences reported first quarter 2017 revenues of $48.4 million, up from $35.2 million in the previous quarter, demonstrating accelerating adoption of its Cologuard colorectal cancer screening test.
Exas july 2017 corporate presentation finalExact Sciences
This corporate presentation discusses Exact Sciences' mission to help eradicate colon cancer through early detection. It summarizes the company's Cologuard test, which detects colorectal cancer through a non-invasive stool DNA test. The presentation outlines Cologuard's clinical validation and success in increasing early cancer detection rates and patient compliance with screening. It also reviews Exact Sciences' commercial strategy, growth opportunities, and expanding pipeline of non-invasive liquid biopsy tests to detect additional cancers.
3.31.17 exas april 2017 corporate presentationExact Sciences
This corporate presentation discusses Exact Sciences' mission to help eradicate colon cancer by partnering with various stakeholders. It summarizes the company's Cologuard test, which non-invasively screens for colorectal cancer with high sensitivity. Cologuard saw strong growth in 2016 and the presentation outlines Exact Sciences' commercial strategy and pipeline expansion into liquid biopsy tests for additional cancer types in collaboration with Mayo Clinic.
3.31.17 exas april 2017 corporate presentation v2Exact Sciences
Exact Sciences is working to establish Cologuard as the new standard for colon cancer screening by:
1) Increasing adoption through a national TV campaign and primary care sales force focused on educating physicians.
2) Growing revenue and test volume rapidly, with 152% revenue growth and over 68,000 tests completed in Q4 2016.
3) Expanding coverage with 77% of the addressable population now covered, including Medicare, following inclusion in screening guidelines.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
This document provides an overview of Cancer Genetics, Inc. It discusses the company's focus on empowering personalized cancer treatment through molecular diagnostics. The summary highlights Cancer Genetics' proprietary diagnostic products for various cancers, partnerships with biopharma companies, growth in revenue and testing volume in 2013, and pipeline of diagnostic tests in development. It also outlines the company's business model and strategy to commercialize its products to target markets globally.
Cancer immunotherapy is becoming a mainstream treatment for cancer. It works by activating the body's own immune system to attack cancer cells. Immunotherapy treatments include checkpoint inhibitors that help activate T cells to kill tumors, and cancer vaccines that stimulate the immune system. Immunotherapy is now approved for several types of cancer and is being studied in combination with other therapies to make treatments more effective with fewer side effects than chemotherapy.
FLAACOs 2014 Conference - Cancer Care in an ACO LandscapeMARCYINC
This document provides an overview of cancer care in Accountable Care Organizations (ACOs) presented by Kelly Blair, COO of Oncology Resource Networks. It notes that cancer costs are rising without improved quality. The landscape is evolving towards value-based contracts between payers and providers and more ACOs. Oncology presents challenges for ACOs due to its complexity and costs, but oncologists are well-suited in some ways. The document provides advice on exploring partnerships with like-minded providers and establishing patient-centered care, aligned incentives, evidence-based guidelines, and monitoring performance to improve outcomes and lower costs in high-performing oncology networks.
Don’t miss our upcoming webinars: Subscribe today!
In this webinar:
Join our presenters, Wayne Critchley from Global Public Affairs and Ryan Clarke from Advocacy Solutions, and CCSN to learn more about changes to the Patented Medicine Prices Review Board (PMPRB) and receive guidance about how to support the cancer community’s engagement at this stage of regulatory reform.
View the video:
https://youtu.be/4IsiptCD0Tw
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Designed this online educational booklet for Association of Community Cancer ...Vickie Spindler
This document summarizes the findings from a focus group and survey conducted by the Association of Community Cancer Centers (ACCC) regarding venous thromboembolism (VTE) risk assessment, prevention, and management for cancer patients in outpatient settings. The focus group and survey found significant variability in VTE risk assessment and documentation. Few oncology practices have formal protocols for VTE risk assessment or use tools to calculate risk. Additionally, VTE prevention and education for patients is not standardized. The document provides opportunities for improvement, including developing formal VTE assessment and order protocols, incorporating risk assessment into electronic health records, and improving patient education about VTE risk and prevention.
Exact Sciences Corporate Presentation: June 2016Exact Sciences
- The corporate presentation provides an overview of the company's mission to help eradicate colon cancer through partnerships with various stakeholders. It highlights key facts about colon cancer incidence and mortality rates.
- Cologuard, the company's non-invasive stool DNA screening test, is described as addressing the colon cancer challenge through multi-target screening with high sensitivity and specificity rates confirmed in clinical studies.
- The presentation outlines the large market opportunity for Cologuard given the underutilized colon cancer screening rates in the US and Cologuard's inclusion in medical guidelines and recommendations.
This corporate presentation provides an overview of Exact Sciences and its colorectal cancer screening test Cologuard. It summarizes Cologuard's clinical trial results showing high sensitivity and specificity. The presentation outlines the large market opportunity for Cologuard given the prevalence of colorectal cancer and low screening rates in the US. Exact Sciences' commercial strategy includes expanding insurance coverage, increasing physician adoption through sales and marketing efforts, and driving patient demand with a national TV advertising campaign. Financial guidance projects over $90 million in revenue and processing over 240,000 Cologuard tests in 2016.
This corporate presentation discusses Exact Sciences' non-invasive colon cancer screening test, Cologuard. It summarizes key points about colon cancer as the second deadliest cancer in the U.S. and highlights Cologuard's superior performance in detecting cancer and precancer compared to other screening options based on clinical trial results. The presentation also provides an overview of Exact Sciences' commercial strategy and growth plan to increase awareness and adoption of Cologuard for colon cancer screening.
Exas august 2017 corporate presentation finalExact Sciences
This corporate presentation discusses Exact Sciences' mission to help eradicate colon cancer through early detection. It summarizes the company's Cologuard test, which detects colorectal cancer through a non-invasive stool DNA test. The presentation outlines Cologuard's clinical validation and notes it is included in major guidelines. It also reviews Exact Sciences' commercial strategy of increasing awareness, access, and compliance through a sales force, marketing campaigns, and focus on improving health outcomes. Financial results for the second quarter of 2017 show increased revenue and cash on hand compared to the prior quarter.
Exas september 2017 corporate presentation finalExact Sciences
Exact Sciences presented their corporate strategy in September 2017. They discussed their mission to help eradicate colon cancer by partnering with various stakeholders. They highlighted that Cologuard addresses the challenges of colon cancer as a non-invasive screening test with high early-stage cancer detection rates. Exact Sciences also reviewed Cologuard's growing adoption driven by their commercial strategies like marketing, salesforce, and increasing insurance coverage.
This corporate presentation provides an overview of Exact Sciences' colorectal cancer screening test Cologuard and highlights its fourth quarter 2017 performance. Key points include: Cologuard revenue grew significantly in 2017 due to expanded insurance coverage, improved reimbursement rates, and increased marketing efforts. The presentation also outlines Exact Sciences' strategy to continue growing market share and penetration by engaging key audiences like patients, providers, and payers. The goal is to make Cologuard the standard of care for colorectal cancer screening in the United States.
This corporate presentation discusses Cologuard, a non-invasive stool DNA screening test for colorectal cancer. It summarizes Cologuard's strong clinical trial results and growing adoption by physicians and patients. Projections show Cologuard's potential to detect thousands of cancers in 2016 and its multi-billion dollar market opportunity in the large colorectal cancer screening market in the United States.
Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
National Shareholder Meeting 2015 - Exact SciencesExact Sciences
The document provides information about Exact Sciences' 2015 Annual Meeting of Stockholders, including the agenda and proposals to be voted on. The agenda includes the election of directors, an advisory vote on executive compensation, approval of an amendment to the 2010 Omnibus Long-Term Incentive Plan, and ratification of the appointment of an independent registered public accounting firm. Additional sections provide management reports on the company's commercial progress, product pipeline, and financial performance.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Exact Sciences is becoming the leader in advanced cancer diagnostics by extending its Cologuard platform to next-generation liquid biopsy cancer diagnostics. Cologuard addresses the challenge of colorectal cancer screening by providing a non-invasive, easy-to-use test with high early-stage cancer sensitivity. Cologuard's commercial success is driven by expanding insurance coverage, growing physician adoption, and direct-to-consumer marketing campaigns.
This corporate presentation discusses Exact Sciences' colorectal cancer screening test Cologuard. It summarizes clinical trial results showing high cancer detection rates and moderate specificity. The presentation notes growing awareness, adoption and reimbursement of Cologuard among physicians and insurers. Exact Sciences expects continued expansion of Cologuard use through sales force growth, increased insurance coverage and integration with electronic medical records.
The document discusses liquid biopsies and next generation cancer molecular diagnostics. It summarizes that OncoCyte Corporation is focused on developing diagnostic tests for early cancer detection using liquid biopsies, with an initial focus on tests for lung cancer. Key points include that lung cancer diagnostics represents a large market opportunity and that OncoCyte's preliminary lung cancer diagnostic test shows strong performance in clinical trials with high sensitivity and specificity. The test has the potential to reduce risky follow-up procedures for patients and provide significant healthcare cost savings.
Kevin Conroy, CEO of Exact Sciences, presented at the 36th Annual J.P. Morgan Healthcare Conference. He discussed Exact Sciences' vision of helping win the war on cancer through early detection using Cologuard. Cologuard demand continues to grow, with over 900,000 people screened and 4,300 early-stage cancers detected since launch. Exact Sciences reported preliminary unaudited Q4 2017 revenue of $86.9-$87.9 million and full year revenue of $265.5-$266.5 million, representing strong year-over-year growth. Exact Sciences is also investing in expanding infrastructure, marketing, and its product pipeline to pursue a multi-billion dollar market opportunity in col
- IDXG provides molecular diagnostic tests for cancer risk assessment and prognosis.
- Recent accomplishments include new product launches, reimbursement from Aetna for ThyraMir, and achieving approval in New York State.
- The presentation provides financial information, with revenue growing but losses continuing from investments in sales, R&D and administrative expenses.
This presentation provides an overview of Interpace Diagnostics Group (IDXG), a commercial company that provides molecular diagnostic tests and pathology services. Key points:
- IDXG has proprietary molecular diagnostic tests for pancreatic cysts (PancraGEN), thyroid nodules (ThyGenX/ThyraMIR), and Barrett's esophagus (BarreGEN).
- Clinical studies show PancraGEN more accurately determines cancer risk of pancreatic cysts compared to current guidelines. ThyGenX/ThyraMIR combination testing can accurately rule in or rule out thyroid cancer risk.
- The tests have significant market opportunities and address unmet clinical needs to avoid unnecessary surgeries and
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
2. Safe harbor statement
Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should,"
"could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this
presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of
forward-looking statements include, among others, statements we make regarding 2016 guidance, expected numbers of completed and reported
Cologuard tests, anticipated patient compliance rates, expected future operating results, anticipated results of our sales and marketing efforts,
expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking
statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial
condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and
profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the willingness of health
insurance companies and other payors to reimburse us for our performance of the Cologuard test; the amount and nature of competition from other
cancer screening products and services; the effects of any healthcare reforms or changes in healthcare pricing, coverage and reimbursement;
recommendations, guidelines and/or quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American
Cancer Society and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully
develop new products and services; our success establishing and maintaining collaborative and licensing arrangements; our ability to maintain regulatory
approvals and comply with applicable regulations; the impact of our nationwide television advertising campaign; anticipated contracts with Anthem and
other health insurance companies; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly
Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from
time to time, whether as a result of new information, future developments or otherwise.
2
3. OUR MISSION
To partner with healthcare providers,
payers, patients & advocacy groups to
help eradicate colon cancer
3
4. Source: American Cancer Society, Cancer Facts & Figures 2016; all figures annual
Colon cancer: America’s second deadliest cancer
new diagnoses in 2015
15,690
26,120
41,780 40,890
49,190
158,080
Esophageal Prostate Pancreas Breast Colorectal Lung
Annual cancer deaths
132,700
deaths in 2015
49,700
134,490
new diagnoses
49,190
deaths
4
5. 10+ years
Sources: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz)
Gastro 1997;112:594-692 (Winawer)
Why is colon cancer the “Most preventable, yet
least prevented form of cancer”?
Pre-cancerous polyp
Four stages of
colon cancer
5
6. Sources: SEER 18 2004-2010
American Cancer Society, Cancer Facts & Figures 2016; all figures annual
Detecting colorectal cancer early is critical
9 out of 10
survive 5 years
Diagnosed in Stages I or II Diagnosed in Stage IV
1 out of 10
survive 5 years
60% of patients are diagnosed in stages III-IV
6
7. America’s stagnant colon cancer screening rate
50%
52%
59% 58%
80% 80%
2005 2008 2010 2013 2018 2020
Source: CDC NHIS survey results as published in the CDC’s MMWR between 2006 and 2015
7
Goals
8. Cologuard: Addressing the colon cancer challenge
§ Stool DNA test: 11 biomarkers (10 DNA & 1 protein)
§ FDA-approved & covered by Medicare
List price - $649; Medicare rate - $509
§ Results of 10,000-patient prospective trial
published in New England Journal of Medicine
§ Included in American Cancer Society guidelines &
USPSTF’s draft guidelines as an alternative test
Source: Imperiale TF et al., N Engl J Med (2014)
Developed with
Mayo Clinic
8
9. A multi-billion dollar U.S. market opportunity
U.S. market opportunity
for Cologuard
$4B
Potential 80M-patient
U.S. screening market*
***
*80 million average-risk, asymptomatic people ages 50-85
**Assumes unscreened decreases from 42% to 30%
***Assumes 24M people screened with Cologuard every three years with ASP of $500
9
10. Sources:
1 Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370: 1287-1297.
2 Redwood DG, Asay ED, Blake ID, et al . Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc 2016; 91: 61-70.
3 Berger BM, Schroy PC, 3rd, Dinh TA. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Inter-test Interval on Clinical Effectiveness. Clin
Colorectal Cancer 2015.Epub ahead of print.
4 Berger BM, Parton M, Levin B, USPSTF Colorectal Cancer Screening Guidelines: An Extended Look at Multi-Year Interval Testing, Am J Managed Care 2016 22(2):e77 – e81.
5 Cologuard’s patient compliance rate is derived from the number of valid tests reported divided by the number of
collection kits shipped to patients during the 12-month period ending 60 days prior to March 31, 2016..
6 Abola MV, Fennimore TF, Chen MM, et al. DNA-based versus colonoscopy-based colorectal cancer screening: patient perceptions and preferences. Fam Med Commun H 2015; 3: 2-8.
Comprehensive case for Cologuard
Cancer detection >90% in two studies1, 2
Superior performance
Versus other screening methods3
Cost-effective
Analysis of independent modeling4
3-year interval
69% compliance with Cologuard kits shipped5
Compliance program
75% of patients consider more suitable than colonoscopy
84% of patients would repeat Cologuard, if recommended6
Patient
satisfaction
10
12. 1FDA Advisory Panel material, Epigenomics AG PMA P130001, March 26, 2014
2Company website
3Company news release dated Feb. 17, 2016
4Stages I-II; does not report Stage I only
55-assay panel
Blood-based colon cancer tests not currently viable
(clean colon)
Low sensitivity for early-stage cancer & high false positive rate
*Not prospective,
not average risk &
not peer-reviewed
Interval Sensitivity
All stages
Sensitivity
Stage I
Specificity Lifetime
False+
3 years 92% 90% 90% 1.2
Epigenomics
Epi proColon
(Septin 9)1
1 year 68% 41% 79% 7.4
Applied
Proteomics*
SimpliPro2
1 year 81% 75%4 78% 7.7
VolitionRx*
NuQ3 1 year 81% 75%5 78% 7.7
12
13. Source: American Journal of Managed Care, February 2016
Virtually no adherence to annual colon cancer screening
3 of 1,000 continuously-insured people adhere to FIT / FOBT recommendations
13
14. $11,313
per QALYs
$15,500
per QALYs
$30,000
per QALYs
Modeling supports Cologuard as cost-effective
3 years
cervical
cancer
3 years 2 years
breast
cancer
QALYs: Quality adjusted life years saved
Source: Berger BM, Schroy PC, 3rd, Dinh TA. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the
Effect of the Intertest Interval on Clinical Effectiveness. Clin Colorectal Cancer 2015.Epub ahead of print.
Cologuard compares favorably with established screening strategies
14
15. Zauber A, et. al. “Evaluating the Benefits and Harms of Colorectal
Cancer Screening Strategies: A Collaborative Modeling Approach.”
AHRQ (2015). See Appendix Tables 3(a) – 10(c).
CISNET modeling highlights Cologuard 3-year has
superior benefits-to-harms ratio
Complications per thousand
Life years gained per thousand
Deaths averted per thousand
15
16. Cologuard increases patient compliance
16
USMD study highlights opportunity to expand screening & detect curable-stage cancer
American Association of Cancer Research Annual meeting 2016, New Orleans LA USA, LB-296,
Proceedings of the American Association of Cancer Research, in press
Non-compliant
Medicare
patients
393 Cancers in
curable stage;
21 advanced
adenoma
4
Cologuard
compliance
88%
17. 17Source: Mayo Clinic poster presentation Su1044, Digestive Disease Week 2016
Knowledge of positive Cologuard
improves Colonoscopy performance
2xPolyps
discovered
46% more time spent
on colonoscopy
Mayo Clinic study compares results of unblinded, blinded colonoscopies
18. Increasing America’s screening population
49% screened with
colonoscopy
Screening history of Cologuard users
42% never
screened before
Source: Colorectal Cancer Screening with Multi-target stool DNA-based Testing Previous Screening History of the Initial Patient Cohort, poster presented at American College of
Gastroenterology's Annual Scientific Meeting (ACG 2015), Oct. 16-21, 2015; ages 50-74
9% screened only
with FIT/FOBT
4 in 10 Cologuard users never previously screened
18
20. Only 24/7/365 nationwide colon cancer screening
network drives compliance
69%
Patient
compliance*
Cologuard’s patient compliance rate is derived from the number of valid tests reported divided by the number of
collection kits shipped to patients during the 12-month period ending 60 days prior to March 31, 2016. 20
21. Three-pronged commercial strategy
Physicians
Primary care
sales force
National TV campaign
Digital marketing
Payers
Clinical & health
publications
Market access
team
Guidelines
Patients
Public relations
Multi-channel
direct to consumer
National TV campaign
21
22. Cologuard’s growing physician penetration
*IMS data based on heart drug prescriptions
August
2014
March
2016
4,100
8,300
14,700
21,000
27,000
200,000 potential Cologuard prescribers*
22
32,000
Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016
23. Strong customer satisfaction with Cologuard
Physicians
expectations
met or exceeded 98%
Patients rated
Cologuard experience
very positive88%
Sources: ZS survey conducted for Exact Sciences, n=300
Exact Sciences Laboratories patient satisfaction survey data is cumulative; n = 2,799
23
24. Source: Imperiale TF et al., N Engl J Med (2014)
Exact Sciences internal estimates based upon prevalence and detection rates from DeeP-C study
2015 results demonstrate Cologuard’s impact
Cancers potentially detected
104,000
completed
Cologuard tests
600
cancers
500
early-stage
cancers
24
25. 25
Targeted TV ads impacting ordering & adoption
Cologuard
orders +50%
New
physician
adoption +100%
Average boost in
test vs. control markets
Ad available at CologuardTest.com
Percentage point growth compares 9-week average between TV test and control markets.
Tested in 5 markets between January – March 2016: Atlanta, Baltimore, Milwaukee/Madison, Sacramento & Tampa Bay
26. Quality
of care
Strategy to advance coverage to contracting
Cost
savings
Member
satisfaction
Value proposition for payers
NEJM publication
shows 92% sensitivity
Easy, non-invasive test;
69% patient compliance
Cologuard delivering
positive budget impact$
26
27. 46% 46%
8%
Source: US Census 2013 and AIS Directory of Health Plans: 2015; ages 50-85
27
Medicare Commercial
Military &
Medicaid
Breakdown of current U.S. insurance market
~80M average-risk people age 50-85
28. Cologuard covered by Medicare
69%
31%
Medicare
Advantage
Traditional
fee-for-service
Medicare
Source: US Census 2013 and AIS Directory of Health Plans: 2015; ages 50-85
More than 37M average-risk Medicare patients ages 50-85
28
Medicare Advantage
plans are required to
treat Cologuard as an
in-network benefit for
cost-sharing purposes
29. 75% 25%
Pursuing Coverage Covered
Source: US Census 2013 and AIS Directory of Health Plans: 2015; ages 50-85
Achieving 25% commercial coverage for Cologuard
29
58 million lives covered by
commercial plans, including:
• Anthem
• Horizon BCBS
• BCBS Massachusetts
• CareFirst BCBS
• Independence Blue Cross
• BCBS Louisiana
• Excellus BCBS
• Harvard Pilgrim Healthcare
• Tufts Health Plan
• Government Employees
Health Association
• Priority Health
• Johns Hopkins Health Plan
30. § Insures 37.6 million people nationwide
§ Second largest insurer in U.S.
§ Anthem enters into agreements by network/region
• Currently contracted: CA, VA and GA
• Latest contracts completed as of June 1: IN, KY, MO, OH and WI
• ~70% of Anthem’s members live in these regions
Sources: Estimate based on US Census data and enrollees
AIS Directory of Health Plans: 2015
Anthem contracting progressing quickly
30
31. 100%
31
Insurance coverage drives order growth
Growth rates measured from March 29, 2015 to March 26, 2016
Percentage-point increase in
order growth in 10 states with
highest insurance coverage,
compared to rest of country
33. First-Quarter 2016 financial results
Revenues
Operating expenses
Cash utilization
Cash balance
33
First Quarter
2016
$14.8 million
$53.7 million
$44.3 million
$262.6 million
34. 80M-person addressable market
Low satisfaction, compliance with
historically-available options
Strong intellectual property protection
Costly 5-10 year product development,
FDA and CMS pathway to approval
Compliance engine
3-year adherence drives recurring revenue
Cost and satisfaction
Near-term savings; increasing screening rates
High product
satisfaction
Patients and physicians want Cologuard
Met or exceeded expectations of 98% of physicians;
88% of patients rated experience very positive
Value to payers
Only national network
for CRC screening
High barrier to entry
Large market
opportunity
Cologuard: An opportunity for long-term growth
34